C3G/Primary IC-MPGN EAP

Clinical trial NCT04729062 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT04729062
Sponsor: Apellis Pharmaceuticals, Inc.
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

C3G IC-MPGN C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G)Complement 3 Glomerulonephritis Dense Deposit Disease DDD Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.